HBW Insight is part of Pharma Intelligence UK Limited

This site is operated by Pharma Intelligence UK Limited, a company registered in England and Wales with company number 13787459 whose registered office is 5 Howick Place, London SW1P 1WG. The Pharma Intelligence group is owned by Caerus Topco S.à r.l. and all copyright resides with the group.

This copy is for your personal, non-commercial use. For high-quality copies or electronic reprints for distribution to colleagues or customers, please call +44 (0) 20 3377 3183

Printed By

UsernamePublicRestriction

US Supplement Industry Growth Robust, But Stronger With Regulatory Help– NBJ Founder

Executive Summary

Businesses offering products with undisclosed drugs or labeled with violative claims and the absence of a federal regulation on lawful use of hemp ingredients in supplements are impediments to growth, says Thomas Aarts, NBJ founder currently managing director of Nutrition Business Advisors.

You may also be interested in...



CBD Will Be US FDA’s ‘One’ Lawful Hemp Compound, House Appropriators Anticipate

Reference in report accompanying House Appropriation Committee bill for FDA FY2023 budget isn’t binding and wasn’t appropriators’ first mention of agency’s response to de-scheduling hemp as a controlled substance. But their ’ statement was more pointed than in previous appropriation reports.

From: US FDA; To: Supplement Industry – Tis The Season To Note Disease Claims, Undeclared Drugs

FDA wraps end-of-year greetings to supplement industry about drug-spiked products labeled as supplements in a bow with officials sharing annual update of their oversight of the industry during a food and drug regulation gathering.

Consumer E-commerce Comfort Helps Amazon Health Product Sales Jump 50%

Amazon’s nutrition and wellness sales soared 55% in 2018 to around $2.5bn and health product sales, including OTC drugs, jumped 50% to about $600m, as consumers grow more comfortable purchasing health products online, says e-commerce market research firm Edge by Ascential.

Topics

Latest News
See All
UsernamePublicRestriction

Register

RS152760

Ask The Analyst

Ask the Analyst is free for subscribers.  Submit your question and one of our analysts will be in touch.

Your question has been successfully sent to the email address below and we will get back as soon as possible. my@email.address.

All fields are required.

Please make sure all fields are completed.

Please make sure you have filled out all fields

Please make sure you have filled out all fields

Please enter a valid e-mail address

Please enter a valid Phone Number

Ask your question to our analysts

Cancel